Medicare Caps Oral Cancer Drug Costs and Expands Payment Options in 2025
New Medicare Part D rules in 2025 cap oral cancer drug costs at $2,000 annually and introduce a voluntary monthly payment plan to improve affordability for patients.
Study Finds Medicare Advantage Patients Face Longer, Costlier Radiotherapy Than Traditional Medicare
New Harvard study compares radiotherapy utilization and spending between Medicare Advantage and Traditional Medicare, highlighting longer treatment durations and higher costs for MA patients.
Medicaid Expansion Boosts Quick Access to Quality Lung Cancer Treatment
Recent study links Medicaid expansion under the Affordable Care Act to enhanced lung cancer treatment, with quicker surgeries at high-volume hospitals and better patient outcomes.